News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lumiphore Inc. Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse


10/2/2008 7:35:41 AM

RICHMOND, Calif., Oct. 1 /PRNewswire/ -- Lumiphore, Inc., a biotechnology leader in the development of new proprietary fluorescent metal-lanthanide technology for use in high-value applications, announced that it has signed an exclusive agreement with Biophor Diagnostics, Inc., Redwood City, California to apply Lumiphore products in diagnostic tests for drugs of abuse.

Under the agreement, Biophor Diagnostics holds the exclusive worldwide rights to Lumi4(TM) technology in current and future diagnostic tests of this type. Lumi4(TM) fluorescent metal-reporter compounds bring increased sensitivity, stability, and robustness to assays in the drugs of abuse testing market through their excellent fade-resistant photophysical properties.

This is the third strategic partnership reached by Lumiphore in the past three years. Previous partnerships include Cis Bio International (http://www.htrf.com/company/partners/) for the drug discovery research market and Echelon Biosciences Inc. (http://www.echelon-inc.com) for novel cancer assays involving phospholipid signaling and lipid-protein interactions.

The company today also announced the appointment of Dr. David J. Ecker to its board of directors. Dr. Ecker is Chief Scientific Officer and a founder of Ibis Biosciences and a co-founder and Vice President of Isis Pharmaceuticals. He brings to the board deep experience in successful biotech commercialization as well as specific technical expertise in detection and assay platforms.

Dr. Ecker has over 24 years of experience in the pharmaceutical/biotechnology industry in cancer and infectious disease research and development. He was a primary inventor of the Ibis T5000 biosensor technology, and has authored more than 80 scientific publications and over 50 U.S. patents. His extensive publications span biosensor technology, infectious disease research, biodefense and gene construction/expression. His previous experience includes assistant director, Department of Molecular Genetics at SmithKline and French (now GlaxoSmithKline).

About Lumiphore | Based in Richmond, California, Lumiphore is a biotechnology leader in the development of proprietary fluorescent-metal lanthanide technology for use in high-value applications which are commercialized through market-specific alliances with corporate partners. Lumiphore has exclusive licenses to the basic science developed at the University of California, Berkeley in the laboratory of Professor Kenneth N. Raymond, a world expert on lanthanide chemistry. Metal lanthanide reporters provide increased sensitivity for fluorescent reagents in biology through time-resolved detection which vastly improves assay signals over background noise. For more information about Lumiphore, log onto http://www.lumiphore.com.

Lumi4(TM) is a trademark of Lumiphore, Inc.

CONTACT: Stephen Blose, +1-415-381-4457, for Lumiphore, Inc.

CONTACT: Stephen Blose, +1-415-381-4457, for Lumiphore, Inc.

Web site: http://www.lumiphore.com/
http://www.htrf.com/company/partners/
http://www.echelon-inc.com/
http://www.nextphasecommunications.com/


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES